Idera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clinical Research on IMO-2125

Idera Pharmaceuticals (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases, today announced it has entered into a clinical development support agreement with Pillar Partners Foundation.  Under the terms of the agreement Pillar Partners will provide direct funding to support three investigator initiated clinical trials to further strategically expand the clinical research of IMO-2125, Idera’s toll-like receptor 9 agonist into broader melanoma populations and other solid tumors.

As quoted in the press release:

“We are eager to expand our knowledge and understanding of the various cancer types and combinations in which IMO-2125 can play a significant role in improving outcomes beyond our current registrational focus with our ILLUMINATE 301 program,” stated Joanna Horobin, M.B., Ch. B., Idera’s Chief Medical Officer. “We look forward to working with these investigators to provide the support they need to initiate these trials before the end of the year,” said Shah Rahimian, MD, Idera’s Oncology Medical Lead. ”

“We have long believed and understood that the mechanism for IMO-2125 has broad potential and plays a central role in IO combinations beyond PD-1 refractory melanoma and through this financial grant, we are able to help light the spark to further expand our ability to test this hypothesis in multiple tumor types with expert clinical investigators,” stated Youssef El Zein, Managing Partner, Pillar Invest Corporation.

Click here to read the full press release.